厄洛替尼治疗老年非小细胞肺癌者的疗效和安全性

Efficacy and Safety of Erlotinib Hydrochloride Tablets (Tarceva) in the Treatment of Elderly Patients with Non-small Cell Lung Cancer

本研究通过厄洛替尼对老年非小细胞肺癌(NSCLC)患者的治疗,观察其临床治疗效果和治疗安全性。回顾性分析2013年1月到2015年1月入住我院的46例老年非小细胞肺癌为研究对象,随机分为观察组和对照组,对照组吉非替尼治疗,观察组厄洛替尼进行治疗,总结厄洛替尼治疗老年非小细胞肺癌临床治疗效果与安全性。治疗后,症状缓解率达到75%,咳嗽、气短症状缓解最为明显,中位时间15 d。19例患者口服厄洛替尼后CEA数值下降,其中4例患者自行缓解,7例患者CEA持续增长。临床症状部分缓解、病情稳定和疾病进展的患者分别有6例、9例和8例,治疗客观有效率和疾病控制率分别为26.09%和65.21%,患者中为无进展生存期和总生存期分别为27周和47周;治疗期间出现的皮疹、腹泻、口干、口腔溃疡、食欲下降等不良反应的患者分别有11例(47.83%)、6例(26.09%)、2例(8.70%)、2例(8.70%)和2例(8.70%),研究过程中未出现一例患者因不良反应而死亡或者退出本次研究。皮疹患者给予皮肤消毒、松软膏等后逐渐好转,不影响继续治疗。腹泻症状出现在服药后1周后,口服止泻药物后得到好转,多为Ⅰ度和Ⅱ度,不影响患者继续治疗。研究结果表明厄洛替尼治疗可以有效的控制老年非小细胞型肺癌患者的病情,治疗过程中毒副反应较轻微,可以作为老年非小细胞肺癌治疗药物之一。需要注意的是不同人群及个体对药物特异性不同,因此在采用厄洛替尼治疗中,需要个性化给药,减少不良反应的出现。

In this study, clinical effect and safety were observed by Erlotinib Hydrochloride Tablets （Tarceva） on the treatment of senile non-small cell lung cancer （NSCLC）. A retrospective analysis from January 2013 to January 2015 in our hospital, we summarized the clinical therapeutic effect and safety in the treatment of senile non-small cell lung cancer, choosing 46 cases of elderly patients with non-small cell lung cancer, 23 cases with the treatment of gefitinib and others with the treatment of erlotinib, as research subjects. After treatment, remission rate reached 75%; cough and shortness of breath were the most obvious symptoms; and the median time was 15 d. After oral erlotinib, CEA value of 19 patients decreased, 4 patients relieved themselves, and CEA of 7 patients continued growing. Patients in clinical symptoms part, in a stable condition, and in a disease progression were 6 cases, 9 cases and 8 cases, separately. Treatment objective effectiveness and disease control rates were 26.09% and 65.21% respectively. Patients with the median progression-free survival and overall survival were 27 weeks and 47 weeks respectively. During the treatment, patients with the adverse reactions, such as skin rashes, diarrhea, dry mouth, oral ulcer, and loss of appetite were 11 cases （47.83%）, 6 cases （26.09%）, 2 cases （8.70%）, 2 cases （8.70%） and 2 cases （8.70%）, respectively. The research process did not appear the condition of death or out of the study due to adverse reactions. Patients with skin rashes gradually improved in the treatment of disinfection and soft paste, and did not affect the continued treatment. After taking the oral antidiarrheal drugs with the treatment of diarrhea symptoms one week, patients got better, mostly I degree and 1I degree; it did not affect the patient to continue treatment. The results showed that Erlotinib （Tarceva） in the treatment of elderly patients with non-small cell lung cancer can effectively control the illness. The effect of poisoning was mild during the treatment. It was able to become a drug treatment of elderly non-small cell lung cancer. It noted that when the use of erlotinib treatment, prescribing medicine should be personalized, and could reduce the occurrence of adverse reactions due to the different people and different individuals on drug-specific.